News > Latest News

Walk News | Sponsor & Foundation News | News in the Parkinson's Disease Community

Adamas Presents New Data Analysis Demonstrating that GOCOVRI™ Reduces Transitions between Dyskinesia and OFF Episodes Throughout the Day


(June 25, 2018) - Adamas Pharmaceuticals, Inc. today announced the presentation of new data analysis of GOCOVRI™ (amantadine) extended release capsules, from the Phase 3 pivotal studies, demonstrating that the reductions in both dyskinesia and OFF experienced by GOCOVRI-treated patients results in longer periods of ON time without troublesome dyskinesia and reduced transitions between Parkinson’s disease diary states. The analysis will be presented in an oral poster at the 2nd Annual Pan American Parkinson’s Diseases and Movement Disorders Congress in Miami, FL. Read more…